Literature DB >> 18726158

Diagnosis and treatment of mood disorders in adults with developmental disabilities.

Diana J Antonacci1, Nadir Attiah.   

Abstract

While the idea that individuals with developmental disabilities (DD) can suffer from mental illness has been largely accepted since the late 1980's, this is still an underserved and poorly studied population. In particular, mood disorders have traditionally been misdiagnosed, under-recognized and poorly treated. Through the years, reported rates of mood disorders in adults with DD have varied widely. Recent epidemiological studies have focused on community samples and find rates of mood disorders from 3 to 8.1%. Mood disorders are found to be more prevalent than psychotic disorders or anxiety disorders. The empirical literature on assessment of mood symptoms in adults with DD is limited, particularly in individuals with severe and profound DD. Several tools have been developed to assist in identification and diagnosis. However, the work on their psychometric properties and validity studies is still quite limited. The treatment literature is sparse and focused primarily on pharmacotherapy. This review considers the epidemiology and diagnosis of mood disorders in individuals with DD. Recent developments in assessment are reviewed. The literature regarding pharmacological treatment with antidepressants, mood stabilizers, electroconvulsive therapy and antipsychotics is summarized and the current state of psychological treatments for mood disorders in persons with DD is presented. Implications for clinical care and future research are considered.

Entities:  

Mesh:

Year:  2008        PMID: 18726158     DOI: 10.1007/s11126-008-9079-x

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  95 in total

1.  Bipolar disorder in mentally retarded adolescents.

Authors:  J T McCracken; R P Diamond
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1988-07       Impact factor: 8.829

2.  Development of an instrument to measure Beck's cognitive triad: the Cognitive Triad Inventory.

Authors:  E E Beckham; W R Leber; J T Watkins; J L Boyer; J B Cook
Journal:  J Consult Clin Psychol       Date:  1986-08

3.  The hopelessness scale for children: psychometric characteristics and concurrent validity.

Authors:  A E Kazdin; A Rodgers; D Colbus
Journal:  J Consult Clin Psychol       Date:  1986-04

4.  Adjunctive gabapentin in patients with intellectual disability and bipolar spectrum disorders.

Authors:  M G Carta; M C Hardoy; I Dessì; M J Hardoy; B Carpiniello
Journal:  J Intellect Disabil Res       Date:  2001-04

5.  Applying the developmental perspective in the psychiatric assessment and diagnosis of persons with intellectual disability: part I--assessment.

Authors:  A Dosen
Journal:  J Intellect Disabil Res       Date:  2005-01

6.  Fluoxetine treatment of depression and associated self-injury in two adults with mental retardation.

Authors:  R Sovner; C J Fox; M J Lowry; M A Lowry
Journal:  J Intellect Disabil Res       Date:  1993-06

7.  Patients with and without intellectual disability seeking outpatient psychiatric services: diagnoses and prescribing pattern.

Authors:  A D Hurley; M Folstein; N Lam
Journal:  J Intellect Disabil Res       Date:  2003-01

8.  Assessment of depression in persons with mental retardation.

Authors:  W M Reynolds; J A Baker
Journal:  Am J Ment Retard       Date:  1988-07

Review 9.  DSM-III-R and persons with dual diagnoses: conceptual issues and strategies for future research.

Authors:  P Sturmey
Journal:  J Intellect Disabil Res       Date:  1995-10

10.  Short-cycle manic-depressive psychosis in a mentally handicapped child without family history. A case report.

Authors:  C M Linter
Journal:  Br J Psychiatry       Date:  1987-10       Impact factor: 9.319

View more
  1 in total

1.  Psychiatric diagnoses in older people with intellectual disability in comparison with the general population: a register study.

Authors:  A Axmon; P Björne; L Nylander; G Ahlström
Journal:  Epidemiol Psychiatr Sci       Date:  2017-02-23       Impact factor: 6.892

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.